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Abstract
Background: Tumor heterogeneity is a major obstacle for finding effective treatment of Glioblastoma (GBM). Based on
global expression analysis, GBM can be classified into distinct subtypes: Proneural, Neural, Classical and Mesenchymal. The
signatures of these different tumor subtypes may reflect the phenotypes of cells giving rise to them. However, the
experimental evidence connecting any specific subtype of GBM to particular cells of origin is lacking. In addition, it is unclear
how different genetic alterations interact with cells of origin in determining tumor heterogeneity. This issue cannot be
addressed by studying end-stage human tumors.
Methodology/Principal Findings: To address this issue, we used retroviruses to deliver transforming genetic lesions to glial
progenitors in adult mouse brain. We compared the resulting tumors to human GBM. We found that different initiating
genetic lesions gave rise to tumors with different growth rates. However all mouse tumors closely resembled the human
Proneural GBM. Comparative analysis of these mouse tumors allowed us to identify a set of genes whose expression in
humans with Proneural GBM correlates with survival.
Conclusions/Significance: This study offers insights into the relationship between adult glial progenitors and Proneural
GBM, and allows us to identify molecular alterations that lead to more aggressive tumor growth. In addition, we present a
new preclinical model that can be used to test treatments directed at a specific type of GBM in future studies.
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Introduction
Glioblastoma (GBM) is the most common and most malignant
type of primary brain tumor. It represents one of the deadliest
human cancers, with average survival at diagnosis slightly over
one year. GBM is remarkably heterogeneous, and may actually
represent several distinct entities with different cells of origin,
different genetic lesions and different clinical behaviors [1,2].
Numerous studies have characterized the expression profiles and
genetic alterations found in GBM [3–9]. A recent comprehen-
sive analysis of The Cancer Genome Atlas (TCGA) dataset has
identified four distinct subtypes of GBM; Proneural, Neural,
Classical and Mesenchymal [10]. Interestingly, each of these
subtypes show an enrichment of gene expression signatures from
distinct neural lineages, implying that the expression patterns of
the different subtypes may reflect the phenotype of their specific
cells of origin [10].
A number of studies have used animal models to explore the
process of gliomagenesis [11–27]. Many of these models induced
tumor formation by introducing genetic lesions into the embryonic
or neonatal brain. These various models have given rise to dif-
ferent tumor types, including oligodendroglioma, astrocytoma and
GBM. It is not clear how the genetic alterations and/or the cells of
origin to which these alterations were introduced influence tumor
phenotype in these models. Similarly, it is unclear how age affects
the phenotypic and tumorigenic potential of progenitor cells. This
is relevant to the human situation, since the majority of GBM
occurs in adults, which implies that the cells giving rise to these tu-
mors reside in the adult brain.
There are several different populations of cells in the adult
brain that may have the capacity to form brain tumors, including
neural stem cells in the subventricular zone (SVZ) [18,25,26] and
more differentiated glial progenitors in the subcortical white
matter [17,28]. Furthermore, experiments using the RCAS/tv-a
system have shown that progenitors with the capacity to form
tumors are not restricted to the SVZ, but are distributed th-
roughout the adult brain [29]. Among the adult glial progenitor
populations, the best characterized are the oligodendrocyte
progenitor cells (OPCs) that express PDGFRa, NG2 and Olig2
[28,30–32]. OPCs are widely distributed, both in the white matter
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20041and cortex, and comprise the largest population of cycling cells in
the adult brain [33–37]. Thus OPCs represent an abundant
reservoir of potentially transformable cells.
Different progenitor populations may utilize different mecha-
nisms to regulate proliferation, differentiation and survival.
Therefore, the genetic alterations that are required to transform
them may also differ. In support of this idea, studies looking at
brain tumors that commonly occur in children (ependymomas and
medulloblastomas) suggested that certain subtypes of these brain
tumors arise from discrete populations of neural progenitor cells in
the embryonic brain. Furthermore, these different progenitor cells
are susceptible to the genetic alterations seen in the particular
tumor subtype to which they give rise [38,39]. Specific genetic
lesions are also observed in different subtypes of GBM. Mutations
and loss of heterozygosity of p53 and amplification of PDGFRa
are most frequently seen in the Proneural subtype, while loss of
Pten is observed throughout all subtypes [8–10,40]. However,
much remains to be learned about how the cells of origin and
genetic alterations interact to determine GBM phenotype.
In this study, we have approached this question by developing
mouse models for GBM, which combine retroviral delivery of
oncogenes with conditional deletions of tumor suppressor genes.
This approach has the unique advantages of allowing us to control
the time and location of tumor initiation. Using retroviruses
expressing PDGF and Cre recombinase, we have stereotactically
delivered transforming genetic alterations to a discrete population
of progenitors in the subcortical white matter of adult mice that
harbor floxed tumor suppressor genes. Fate mapping showed
that the retrovirus selectively infects a local population of glial
progenitor cells that predominantly give rise to cells of the
oligodendrocyte lineage. However, we found that the combination
of PDGF expression with genetic deletion of Pten and p53 induces
these cells to form GBM-like brain tumors with 100% pene-
trance. Our results revealed that the mouse tumors closely re-
semble the Proneural subtype of human GBM. Furthermore, both
the mouse tumors and Proneural GBM are highly enriched in
genes expressed by OPCs, providing further evidence for the close
relationship between OPCs and the Proneural GBM. Finally,
using a set of genes that are differentially expressed between mouse
models with different genetic deletions (Pten
f/f vs. Pten
f/f; p53
f/f),
we are able to separate human Proneural GBM into groups with
different molecular and clinical features. Together, these findings
indicate that glial progenitors that reside in the adult white matter
can form brain tumors that recapitulate both the genomic and
phenotypic profile seen in a specific subtype of human GBM.
Results
PIC retrovirus induces GBM-like tumors in mice with
conditional Pten and p53 alleles
We injected VSVG-pseudotyped PDGF-IRES-Cre (PIC) retro-
virus, which expresses PDGF and Cre in one transcript, into
rostral subcortical white matter (WM) of transgenic mice that carry
floxed Pten (Pten
f/f) or floxed Pten and p53 (Pten
f/f; p53
f/f). Brain
tumors with the histological features of human GBM formed with
100% penetrance in both genotypes (Figure 1A–E). However, the
rate of tumor formation differed significantly between these two
genotypes: mice with floxed Pten and p53 (Pten
f/f; p53
f/f) had a
median survival of 27 days post injection (dpi) compared to 85 dpi
for mice with floxed Pten (Pten
f/f). These mice also harbored a
stop-floxed luciferase reporter, as a consequence, only retrovirus
infected cells and their progeny expressed luciferase, allowing us
to monitor tumor growth by bioluminescence imaging. Consistent
with the results of our survival study, the two models showed
marked differences in tumor growth dynamics, with the tumors in
Pten
f/f; p53
f/f mice developing earlier and growing faster than
those in Pten
f/f mice (Figure 1F–H). As controls, we injected PIC
retrovirus into stop-flox luciferase mice with wild type Pten and
p53 and Cre-only retrovirus (no PDGF) into Pten
f/f; p53
f/f mice.
No luciferase signal was ever detected in the control mice (data not
shown), and none of the control mice ever developed tumor
related morbidity (Figure 1A). These results demonstrate that,
when given alone, neither PDGF expression nor deletion of Pten
and p53 is sufficient to induce tumor formation. However, the
combination of PDGF stimulation and deletion of Pten and p53
cooperate to induce tumor formation with remarkable robustness
and consistency.
Tumors from Pten
f/f; p53
f/f mice are predominantly composed
of Pten negative cells, and express high levels of Olig2 and
PDGFRa, markers normally expressed by OPCs (Figure 2A–F).
Many GFAP+ cells are scattered throughout the tumor mass
(Figure 2G and H), and represent entrapped astrocytes (see below).
Similar results were seen with tumors from Pten
f/f mice (data not
shown).
Primary tumor preparations were made from tumors in Pten
f/f
and Pten
f/f; p53
f/f mice. These cells were serially transplanted
intracranially in NOD/SCID mice for up to four generations. We
found that the transplanted cells continue to give rise to tumors
that have the histological features of GBM, with an immunophe-
notype similar to that of the primary tumor (Figure S1). Thus, the
retrovirus-infected progenitor cells are fully transformed and
possess tumorigenic potential with extensive capacity to self-renew.
Furthermore, these cells can be propagated in cultures using
growth conditions that have been optimized for OPCs [17,41].
Immunocytochemical analysis confirmed that these cells conti-
nue to express many OPC markers, including Olig2, PDGFRa,
Nkx2.2, NG2 and Sox10 (Figure S2) as well as markers seen in
glial progenitors and other progenitor populations, such as Sox2,
Nestin and Mash1 (data not shown).
Early stage tumors are composed of proliferating OPCs
To characterize the phenotype of cells giving rise to these
tumors, we injected PIC retrovirus into mice with floxed Pten and
stop-floxed YFP. In these mice, the retrovirus infected cells showed
both Cre mediated deletion of Pten and Cre induced expression
of YFP. The YFP reporter enabled us to identify cells infected by
retrovirus and monitor tumor growth from very early stages. At
3 dpi, a small collection of YFP+ cells was seen at the injection site
(Figure 3A). The YFP+ population was progressively larger at
later time points (7 dpi and 21 dpi) with many YFP+/Pten- cells
infiltrating the surrounding brain tissue (Figure 3B and C). At
3 dpi, more than 70% of the proliferating, retrovirus-infected cells
(YFP and ki67 double positive cells) expressed Olig2 (Figure 3D).
This fraction increased over time, reaching over 90% by 7 dpi
and over 95% by 21 dpi (Figure 3E and F). Interestingly, at early
time points we observed some Ki67+ cells that did not express
YFP. These cells likely represent uninfected glial progenitors that
are being induced to proliferate via paracrine growth factor
stimulation, as previously described [17,22,42]. However, the
YFP- cells at 21 dpi accounted for only ,6% of total number
of proliferating cells (data not shown). This indicates that the
retrovirus infected cells, with Pten deleted, have a significant
selective advantage, and quickly become the predominant popu-
lation within the tumor.
We found that the growing lesion is always centered at the
injection site, demonstrating that the tumor arises from locally
infected cells. By 21 dpi, there is already a well-defined hyper-
cellular lesion (Figure 3J–O). These tumors are predominantly
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PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20041Figure 1. PDGF-IRES-Cre retrovirus induced tumor formation in mice with floxed Pten and p53. (A) Kaplan-Meier curves comparing the
survival of mice from our 4 experimental groups: All PIC injected Pten
f/f mice and Pten
f/f; p53
f/f mice developed brain tumors with median survivals of
85 dpi and 27 dpi, respectively. Three mice from the control groups died from unrelated causes during the study. The remaining control mice were
sacrificed and analyzed at the end of the study, none showed evidence of tumor. The survival differences between all groups were highly significant.
The p values for all comparisons are shown in the right panel. (B–E) Low and high powered micrographs showing H & E stains of end stage tumors in
Pten
f/f mice (B and C) and Pten
f/f; p53
f/f mice (D and E). Both tumors show histological features of GBM, including areas of pseudopalisading necrosis
(N). (F–G) Bioluminescence imaging of tumor growth in Pten
f/f; p53
f/f (F) and Pten
f/f (G) mice. (H) Plot showing the different growth rates of tumors in
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Furthermore,themajorityofKi67+ cycling cellsarealsopositivefor
Olig2, PDGFRa, and YFP+ (Figure 3F and G), demonstrating that
the tumors were arising from retrovirus-infected cells that resemble
proliferatingOPCs.Inaddition,weobservedmanyGFAP+ reactive
astrocytes scattered throughout the tumor. However, none of these
cells are YFP+, ki67+ or Phospho-histone H3 (PHH3)+ (Figure 3H,
K, N and data not shown), suggesting that the GFAP+ cells are not
derived from virally infected cells and do not represent a neoplastic
population. We also observed that as YFP+ cells infiltrate the
surrounding brain tissue they become intermingled with NeuN+
neurons. However, none of the YFP+ cells express the neuronal
marker NeuN (Figure 3I).
To characterize the fate of the retrovirus-infected cells when
Pten was not deleted, we injected PIC retrovirus into subcortical
white matter of mice with wild type Pten and stop-floxed YFP
(YFP mice). We observed that at all time points (3, 17, 94 and
143 dpi), YFP+ cells remain clustered around the injection site.
Immunohistochemical staining for Olig2, PDGFRa and GFAP
shows that the YFP+ populations initially contains a mixture of
astrocytes and OPCs at 3 dpi (Figure S3A). However, by 17 dpi,
more than 70% of YFP+ cells express Olig2 (Figure S3B). As early
as 3 dpi, OPCs account for the majority of Ki67+ cycling cells
(Figure S3C and D). Over time, the Olig2+/PDGFRa+/YFP+
population slowly expands around the injection site and be-
comes the predominant population (Figure S3E and F). We never
observed YFP+ cells in the subventricular zone (SVZ), rostral
migratory stream (RMS) or olfactory bulb (OB) (Figure S3F and
data not shown), confirming that retrovirus injections into sub-
cortical white matter selectively infect a local population of glial
progenitors. In contrast, with PIC retrovirus injection into the
SVZ of the lateral ventricle in YFP mice, many YFP+ cells are
seen in the SVZ, RMS and OB, where some of them eventually
differentiate into neurons (Figure S4). Together, these results
demonstrate that injecting the PIC retrovirus into the subcortical
white matter selectively infects local glial progenitors, and it is this
population that gives rise to brain tumors.
The retrovirus driven mouse tumors resemble human
Proneural GBM
We compared the relationship of the mouse tumors and hu-
man GBM at the molecular scale. Gene expression profiling was
Pten
f/f (blue line) and Pten
f/f; p53
f/f (red line) mice. Each line shows the changes in the mean value of the luciferase signal of 11 mice per group. Bars
show the S.E.M at each time point.
doi:10.1371/journal.pone.0020041.g001
Figure 2. Immunophenotype of end stage tumors is consistent with OPC identity. Each triptych shows the immunostaining (red), Hoechst
nuclear stain (blue) and combined for low power (left) and high power (right) micrographs of ends-stage tumors in Pten
f/f; p53
f/f mice. (A and B) Most
cells in the tumor lacked Pten staining. (C–F)The vast majority of tumor cells express olig2 (C and D) and PDGFRa (E and F). (G and H) GFAP+
astrocytes were scattered throughout the tumor, but represented a minority of cells.
doi:10.1371/journal.pone.0020041.g002
Adult Glial Progenitors Give Rise to Proneural GBM
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20041Figure 3. Phenotypes of early tumor lesions in YFP; Pten
f/f mice indicated OPC identity. (A–C) Schematic views show the distribution of
YFP+ cells (green dots) at 3 dpi (A), 7 dpi (B) and 21 dpi (C). (D–F) Triple immunofluorescence shows YFP (green) ki67 (red) and Olig2 (blue) at 3 dpi
(D), 7 dpi (E) and 21 dpi (F). The arrows in D and E mark triple positive cells. The tables below each panel show the counts of ki67+/YFP+ cells at each
time point (total, Olig2+, and Olig22). (G–I) Triple immunofluorescence shows the expression of different markers in tumor cells at 21 dpi: (G) shows
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f/f and 8 Pten
f/f; p53
f/f),
which were compared to 218 human GBM from TCGA. Of 840
genes that were used to classify human GBM from TCGA into 4
subtypes (Proneural, Neural, Classical and Mesenchymal) [10], 723
orthologs could be mapped to the mouse arrays (see Methods and
Table S1). We adapted the centroid-based classifier in order to use
these orthologs genes [10]. This new classifier wasre-trained and re-
tested on the original TCGA dataset, with the loss in classification
powerwaslessthan 10% (Table S1). The newclassifieralso retained
the capability to sort the same TCGA dataset into four subtypes
(Figure 4A and Figure S5A). Remarkably, all mouse tumors were
classified as Proneural using this modified classifier (Figure 4A,
Table S1). Using these 723 genes, hierarchical clustering showed
that mouse tumors preferentially clustered with the Proneural GBM
(Figure S5A), providing an additional support that these mouse
tumors resemble human Proneural GBM.
Both Mouse tumors and human Proneural GBM are
enriched in OPC genes
We then interrogated a murine dataset that was generated from
neural lineages isolated from mouse brain [43]. From this study we
compiled a list of 369 genes that were derived from 5 gene lists as
published [43], which represented signatures of five cell types:
OPCs, oligodendrocytes, neurons, astrocytes and cultured astro-
glia (see Methods and Table S1). We conducted a Gene Set
Enrichment Analysis (GSEA) using this gene list on the mouse
tumors and human tumors from the TCGA dataset. Both mouse
tumors and human Proneural GBM were enriched with the gene
ki67 (red), YFP+ (green) and PDGFRa+ (blue). (H) shows Olig2 (red), YFP (green) and GFAP (blue). (I) shows Olig2 (red), YFP (green) and NeuN (blue).
(J–O) Low power montage of 21 dpi tumor shows Olig2 (J), YFP (K), PDGFRa (L), Hoechst (M), GFAP (N) and Pten (O).
doi:10.1371/journal.pone.0020041.g003
Figure 4. PDGF driven mouse tumors most resembled human Proneural GBM and express signatures of OPCs. (A) Heat map of the
Pearson correlation based classification of mouse and human GBM samples. Red to blue color scale shows the range from the highest positive to
highest negative correlation. The correlation was computed for both mouse samples and TCGA human GBM. A sample is assigned the class with the
highest correlation coefficients (see Methods for details). (B) Mouse tumors and human Proneural patients were both enriched with OPC genes.
Sample wise: mouse tumors are labeled as black, Proneural as green, Neural as blue, Classical as red and Mesenchymal as yellow. Red to blue color
scale shows the range from the highest to lowest enrichment score. These genes lists are provided in Table S1.
doi:10.1371/journal.pone.0020041.g004
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patients were also enriched with the gene signature of oligo-
dendroctytes. Importantly, neither mouse tumors nor human
Proneural GBM showed enrichment in genes specific for the other
cell types (neuronal, astrocyte or cultured astrocyte). In contrast,
each of the other subtypes of human GBM showed marked
enrichment for genes expressed in one of the other cell types
(Figure 4B). In addition, when sorted with this list, all
mouse tumors in our dataset clustered closely with the OPC
samples in the Cahoy et al. dataset (Figure S5B), providing
additional indication that mouse tumors are enriched in OPC
genes. As an internal control, three normal brain samples in our
dataset clustered with the forebrain sample, and together as a
group, clustered with neurons from the Cahoy et al. dataset
(Figure S5B).
Differential gene expression of mouse tumors revealed
heterogeneity within human Proneural patients
We found that the mouse tumors from both models (Pten
f/f vs.
Pten
f/f; p53
f/f) are remarkably homogeneous with respect to the
expression of Proneural classifier and OPC genes (Figure 4A, B
and Figure S5A, B). However, survival and imaging studies
demonstrate that two models also have very different growth
behaviors, with the combined deletion of Pten and p53 giving rise
to more aggressive tumors (Figure 1A, F–H). To define the
differences between these two models, we performed differential
gene expression (DGE) analysis (see Methods) by comparing the
Pten
f/f vs. Pten
f/f; p53
f/f tumors. This analysis identified 533
differentially expressed genes; 224 genes are expressed at higher
levels in Pten
f/f; p53
f/f tumors compared to Pten
f/f tumors (we
refer to this gene list as ‘‘up in Pten+p53’’), and 309 genes are
expressed higher in Pten
f/f tumors compared to Pten
f/f; p53
f/f
tumors (we refer to this gene list as ‘‘up in Pten’’). 137 of the 224
genes in the ‘‘up in Pten+p53’’ list and 162 of 309 genes in the ‘‘up
in Pten’’ list could be mapped to human microarray platform
(Table S1).
We conducted GSEA to illustrate the enrichment patterns of
these two gene lists in relationship to the two mouse models. An
enrichment score (ES) for each gene list was calculated for every
mouse tumor. The tumors were then rank-ordered based on the
difference between the ES of two gene lists. As expected, this
procedure sorted the mouse tumors according to genotype, with
Pten
f/f and Pten
f/f; p53
f/f tumors showing an inverse relationship
with respect to the ES for two lists of genes, and therefore falling
on opposite ends of the GSEA ranking (Figure 5A). We next used
the same procedure to sort the 59 TCGA human Proneural GBM
into those that more closely resemble one or the other mouse
models. We observed an inverse correlation in those patients at
either ends of GSEA ranking: those with higher ES on the ‘‘up in
Pten+p53’’ list tended to have lower ES on the ‘‘up in Pten’’ list,
and vice versa (Figure 5B).
The heterogeneity of human Proneural patients revealed
by mouse DGE lists correlated with survival differences
We extended the GSEA analysis to three additional datasets
[7,44,45]. Out of the combined 176 patients, 48 were classified as
Proneural GBM (Verhaak RG, Hoadley KA and Hayes DN,
personal communications). Together with 218 TCGA patients,
these 394 (176+218) GBM, of which 107 (48+59) were assigned as
Proneural, is comprehensive and include every GBM with the
subtype known to us. Using the difference in Enrichment Score
(ES), we sorted Proneural patients from each of the datasets (Table
S1). One third of total patients were selected from either end of the
GSEA ranking for each of the 4 datasets, because their tumors
displayed signatures closest to those of Pten
f/f or Pten
f/f; p53
f/f
mouse tumors. The survival data from all these patients were
pooled together. Strikingly, the patients with tumors that
resembled Pten
f/f; p53
f/f mouse tumors lived significantly shorter
than patient with tumors that more closely resembled Pten
f/f
tumors: median survival of 273 days vs. 553 days with p=0.0366
(Figure 5B and C, Table S1). Thus, comparison with the mouse
models allows us to separate Proneural patients into groups with
different clinical outcomes.
The DGE lists contain many genes involved in p53
signaling
The defining experimental difference between our two mouse
tumor models is that one includes p53 deletion as an initiating
genetic alteration, whereas the other does not.
Therefore, we reasoned that Gene Ontology analysis on the
combined DGE list would identify genes whose expression changes
when p53 is deleted. Out of 299 genes (137+162), 8 of them are
members of core p53 signaling pathway, as defined by Ingenuity
Pathways Knowledge Base (see Methods). Through them, another
96 genes are connected to p53 signaling pathway (Figure 6A,
Table S1). Thus, the DGE list is highly enriched for genes that are
functionally related to p53. As a master transcriptional regulator,
p53 can either activate or repress target gene expression [46].
Several genes on the DGE list, including Ccng1, Cdkn1a, Fas and
Tnfrsf10, which contain binding sites for p53 in their promoters
and whose expression is activated by p53, are expressed at higher
levels in Pten
f/f tumors vs. Pten
f/f; p53
f/f tumors. Conversely,
several genes that are repressed by p53, such as Bcl2, Fgf2 and
Wee1, are expressed at lower levels in Pten
f/f tumors. Members of
the combined DGE list are also enriched in a variety of biological
functions and diseases, the top of which includes cancer, cell death
and growth (Figure 6B). Not surprisingly, many of these processes
are tightly regulated by p53 [47,48]. Interestingly, 195 genes on
the DGE list were not identified as being related to p53 by the
Ingenuity-based analysis, suggesting that such a relationship has
not previously been established. We propose that these 195 genes
are ideal candidates for extending new connections of p53 in
relation to gliomagenesis. Together, our approach provides a
powerful tool to identify genes whose altered expression leads to
tumor aggressiveness.
Discussion
Glial progenitors in the adult subcortical white matter
can give rise to brain tumors
The question of which cells can give rise to GBM, and where in
the adult brain such cells reside, has long been an area of intense
research and controversy [1,2,49,50]. Many studies have provided
evidence that neural stem cells in the SVZ have the capacity to
form brain tumors [18–20,25,26,51,52]. However, radiographic
data from patients suggests that the origins of GBM are not
restricted to the SVZ and that many tumors arise in the subcortical
white matter [53]. Furthermore, evidence suggested that GBM
arising outside the SVZ may have distinct growth characteristics
and clinical outcomes [54,55]. Therefore, characterizing the
tumorigenic potential of cells that reside outside the SVZ is of
both scientific and clinical interest.
In this study, small volumes of retrovirus (0.4 ml) were injected
into the rostral subcortical white matter (WM), a region that is
anatomically distant from SVZ and enriched in glial progeni-
tor cells. Retroviruses only infect dividing cells [56], and therefore,
can be used to selectively target progenitor cells in the brain
Adult Glial Progenitors Give Rise to Proneural GBM
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identify and fate map the cells that had been infected by PDGF-
IRES-Cre expressing retroviruses. The distinct advantages of this
approach allow us not only to control the timing and location of
tumor initiation, but also to genetically label these cells and
monitor tumor growth from very early stages. By 3 dpi a small
collection of YFP+ cells are seen clustered around the injection
site, and we found that this local population of white matter
progenitor cells gives rise to the subsequent tumors.
Fate mapping showed that none of the cells infected by
retrovirus injected into the subcortical white matter give rise to
neurons. Rather, they exclusively give rise to cells of glial lineage,
predominantly cells of the oligodendrocyte lineage. We also
observed infection of some local GFAP-expressing astrocytes.
We cannot completely rule out the possibility that some of these
retrovirus-infected astrocytes were induced to stop expressing
GFAP and adopt an OPC phenotype in response to aberrant
PDGF stimulation. However, OPC-like cells were the predomi-
nant proliferating population at all time points of tumor
development. Thus, our results indicate that these tumors are
either arising directly from OPCs or from some closely related
white matter progenitor cell that quickly acquires, and retains, an
OPC-like phenotype.
The Proneural phenotype reflects a close relationship to
OPCs
GBM can be divided into subtypes on the basis of global gene
expression [7,10]. Using the same approach as published [10], we
showed that the mouse tumors are most closely related to the
Proneural subtype. Notably, the set of 210 classifier genes used to
define the Proneural subtype contains many OPC genes, including
Olig2, Nkx2.2, ErbB3, Sox4 and others (Table S1). In fact, 94 of
the 210 (.45%) Proneural classifier genes are enriched in OPCs
[10,43] (Table S1). It was previously shown that Proneural GBM
express genes that are associated with the oligodendrocyte lineage
[10]. To further explore this issue, we expanded the analysis to
compare the expression of genes that are enriched in OPCs to that
of other cell types isolated from the mouse brain [43]. We showed
that the mouse tumors and human Proneural GBM were both
consistently enriched in OPC genes, but not in the signature genes
of other cell types (oligodendrocytes, neurons, astrocytes or
cultured astroglia). These results provide further evidence for the
close relationship between Proneural GBM and OPCs.
PDGF signaling is a functional link between OPCs and
Proneural GBM
Certain common genetic alterations tend to occur in specific
GBM subtypes [10]. This raises the possibility that these genetic
alterations are particularly effective at transforming the cell type
that gives rise to the specific GBM subtype. Amplification of the
PDGFRa receptor is most commonly seen in Proneural GBM
[2,10]. Furthermore, proteomic studies revealed that activation of
PDGF signaling is associated with Proneural phenotype [40].
PDGFRa is selectively expressed in OPCs in the normal brain
[60–64], and the ability of PDGF signaling to stimulate the
proliferation and migration of OPCs is well established [61,64–
69]. Similarly, several experimental models have shown that
PDGF stimulation can induce the formation of gliomas
[11,12,14,17,22,42]. In particular, one study using the RCAS/
tv-a system has shown that PDGF is sufficient to induce neonatal
OPCs to form gliomas that resemble low-grade oligodendroglio-
mas [21]. In our model the tumors show the histological features of
GBM. Furthermore, we show that these tumors have a Proneural
phenotype and are also highly enriched in expressing OPC genes.
While it is possible that PDGF signaling plays a role in inducing
the expression of Proneural genes, our results suggest that PDGF
responsiveness is an inherent feature of the cells that give rise to
Proneural GBM. Thus, the role of PDGF signaling in OPCs and
Proneural GBM provides a compelling example of how cancer
cells can highjack specific signaling pathways that regulate the
development of those cells from which they arise.
In addition to PDGFRa amplification, other genetic alterations,
including p53 and IDH1 mutations, are strongly associated with
Proneural GBM [10]. We propose that OPCs are particularly
sensitive to the transforming effects of these genetic alterations. In
this study, we demonstrated that PDGF stimulation and tumor
suppressor Pten and p53 deletion cooperate to induce PDGFRa
expressing adult glial progenitors to form GBM-like brain tumors.
Using activated EGFR combined with p53 deletions, Persson et al.
provided evidence that OPCs can be induced to form tumors
resembling human oligodendroglioma [27]. The differences in
tumor types seen in the previous studies and our study could
be due to the nature of the genetic alterations introduced and/or
the age of the animal when these alterations are delivered.
Interestingly, it was shown that, in addition to a subset of GBM
[10], oligodendrogliomas are also enriched in the Proneural
signature [70]. Together, these results are consistent with the close
relationship between OPC and the Proneural phenotype.
A recent paper showed that genetically deleting combinations of
tumor suppressors (Pten, Rb1 and p53) in the adult brain with an
inducible Cre system (GFAP-CreER) will give rise to high grade
astrocytomas [71]. These tumors were widely distributed in the
brain and showed a spectrum of phenotypes that resembled the
different subtypes of high grade gliomas as described [7,71]. They
did not find a significant correlation between the types of genetic
alterations used to initiate tumors and the subtypes of tumors that
formed. However, they found an intriguing correlation with tumor
location, suggesting that tumor subtype may be determined by
microenvironment or by the type of cells that gives rise to the
tumor.
Heterogeneity within Proneural GBM is correlated with
genetic alterations and clinical outcome
While Proneural GBM cluster into a common group based on
the expression of 840 classifier genes, evidence also suggests that
there is significant heterogeneity within Proneural GBM and that
this heterogeneity may have clinical and prognostic relevance.
Previously, using a list containing 35 genes, high grade glioma
(HGG), including GBM, were classified into three groups: Pro-
neural, Proliferative and Mesenchymal [7]. In this classification
Figure 5. DGE lists reveal heterogeneity in human Proneural GBM. (A) GSEA of mouse tumors with DGE lists of Pten
f/f vs. Pten
f/f; p53
f/f
mouse tumors. Sample wise: Pten
f/f; p53
f/f tumors were labeled as blue and Pten
f/f tumors as green. Red to blue color scale shows the range from the
highest to lowest enrichment score. (B) GSEA ranking of TCGA Proneural patients with DGE lists of Pten
f/f vs. Pten
f/f; p53
f/f mouse tumors. Horizontal
red line on top of panel labels 1/3 of Proneural patients that most resemble Pten
f/f; p53
f/f tumors, while blue line labels 1/3 of patients that most
resemble Pten
f/f tumors. Similar patients from four datasets are pooled together to compare survival as in (C). Sample wise: Proliferative is labeled as
blue, Mesenchymal as red and the rest of Proneural as green (See discussion). (C) Kaplan-Meier survival curve comparison of patients that resemble
Pten
f/f; p53
f/f mouse tumor vs. those that resemble Pten
f/f mouse tumor.
doi:10.1371/journal.pone.0020041.g005
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doi:10.1371/journal.pone.0020041.g006
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with poor prognosis, as defined by shorter patient survival, while
Proneural tumors were associated with better prognosis. When
the Phillips et al. classification system is applied to 59 TCGA
Proneural GBM identified by Verhaak et al. classification system,
40 of 59 TCGA Proneural patients remained as Proneural, while
the other 19 patients were classified as Proliferative (18) or
Mesenchymal (1) [7,10] (Figure 5B). Interestingly, when we
mapped the results of both the Phillips and Verhaak classifica-
tions onto our GSEA ranking, the distribution of the 40 Proneural
GBM identified by both classifiers was significantly skewed
towards the end that more closely resembled Pten
f/f tumors in
mice (Figure 5B).
Our two mouse models (Pten
f/f vs. Pten
f/f; p53
f/f) provide us a
unique tool to understand heterogeneity within Proneural subtype
of GBM. We generated a list of genes that are differentially
expressed between these two mouse models. The list is highly
enriched in genes involved in cancer, cell death and growth, and
many of the genes are known to be functionally related to p53.
Using this gene list discovered in mice, we separated human
Proneural GBM into groups that more closely resembled one or
the other mouse model. Strikingly, there was significant difference
in survival between these groups, with those tumors that more
closely resembled Pten
f/f mouse tumors having a greater than 2
folds longer median survival than those that resembled Pten
f/f;
p53
f/f mouse tumors. Therefore, Proneural GBM can be separated
into prognostically distinct subgroups based on their similarity to
our mouse models.
Analysis of the TCGA dataset suggests that mutation status of
p53 alone does not predict survival in Proneural GBM. However,
the p53 pathway can be compromised by alterations other than
mutations in p53 itself, such as MDM2 amplification [72].
Although our DGE list was identified by comparing tumors with
and without p53 deletion as an initiating genetic lesion, this gene
list likely captures the global changes in expression signatures that
result from overall alterations in p53 signaling.
Recently, a report identified a group of TCGA GBM patients
with a glioma-CpG island methylator phenotype (G-CIMP) [73].
The majority of these patients belongs to the Proneural subtype
and is associated with longer survival [73,74]. Interestingly, these
G-CIMP+ patients are evenly distributed on our GSEA ranking
(Table S1). Furthermore, removing these patients from the data set
caused a similar reduction in median survival from both groups,
but with limited overall impact on the difference in survival
(resembled Pten
f/f vs. Pten
f/f; p53
f/f: median survival 448d vs.
238d, p=0.0315). This suggests that the heterogeneity within
Proneural GBM that has been revealed by our approach is
independent of their G-CIMP status. As is the case with many
prognostic factors identified through analysis of human brain
tumors, G-CIMP status shows a strong correlation with patient
age. In contrast, the gene list identified in our study separates
Proneural GBM patients into prognostically distinct groups that
are independent of age (Table S1). This is likely due to the fact that
our approach allowed us to control for animal age at the time
of tumor induction. Together, these results indicate that p53
signaling alterations play a central role in the malignant tran-
sformation of OPCs as well as in determining aggressiveness of
Proneural GBM.
Conclusions
Our study reveals a close relationship between OPCs and
Proneural GBM. These findings suggest that understanding the
mechanisms that regulate OPC proliferation, differentiation and
survival may lead to new therapeutic targets tailored towards
Proneural GBM. In the process of this study, we also generated
remarkably robust and consistent GBM models in mice, with built-
in luciferase reporters that allow real time imaging of tumor
growth. These models can be used to test the efficacy of new
therapies directed towards Proneural GBM.
Methods
Ethics statement
All experimental procedures involving mice were approved by
the Institutional Animal Care and Use Committee (IACUC) of
Columbia University and performed in accordance with institu-
tional policies.
Retrovirus construction and intracerebral stereotactic
injections
PDGF-IRES-Cre was generated by cloning human PDGF-B
[42] and Cre [75] into pQXIX vector (Clontech). Cre-GFP was
described [76]. VSVG pseudotyped retrovirus was generated
as described in Methods S1. Cre-GFP retrovirus was titered to
10
7/ml in 293 cells. PIC retrovirus was titered to 10
6/ml using
Mouse Embryonic Fibroblasts (MEFs) prepared from stop-floxed
YFP mice [77]. Brain surgery procedures in mice were as
described in Methods S1. For WM targeting, we used the
coordinates of 2.1 mm lateral, 2.2 mm rostral and 1.8 mm deep,
(2.1 mm+2.2 mm+1.8 mm) with bregma as the reference point.
For targeting dorsal lateral corner of SVZ, we used the coordinates
of 1 mm+1m m +2.1 mm, with bregma as the reference. Using a
stereotaxis platform, 0.4 ml retrovirus was injected into the brain
with a Hamilton syringe (flow rate 0.1 ml/min). For serial
transplantation experiments, 2610
4 primary tumor cells were re-
suspended in 2 ml of Opti-MEM (Invitrogen) and injected into
brain with flow rate at 0.2 ml/min. The coordinates for cell
injection were 2 mm+2m m +2 mm, with bregma as the reference.
Transgenic mice
Mice harboring floxed tumor suppressors and stop-floxed
reporters were generated by breeding the following strains: floxed
Pten mice [78], floxed p53 mice [79], stop-floxed YFP mice [77]
andstop-floxedluciferasemice(ThomasLudwig,unpublished).The
resulting mouse lines therefore are on mixed genetic backgrounds.
NOD/SCIDmicewerepurchasedfromJacksonLabs.Allinjections
were done in mice between six and eight weeks of age.
Bioluminescence imaging
100 ml of 30 mg/ml luciferin (Caliper Life Sciences) was
injected intraperitoneally into each mouse. The IVIS Spectrum
(Caliper Life Sciences) was used to capture bioluminescence
images. All mice were imaged between 10 to 15 minutes after
substrate injection (with 1 minute exposures). Mice with active
tumor growth were imaged at least once per week, while control
mice were imaged monthly. All control mice were last imaged at
the conclusion of survival study.
Brain sectioning - histological and immunohistochemical
analysis
Mice were transcardially perfused with 15 ml ice cold PBS,
followed by 15 ml cold 4% paraformaldehyde (PFA). Brains were
removed and fixed overnight at 4 degrees in 4% PFA. Brains were
paraffin embedded and microtome sectioned (5 mm thick) and
then processed for histological analysis with hematoxylin and eosin
stains, or, cryoprotected in 30% sucrose, snap frozen in OCT,
cryosectioned (10 mmo r5 0 mm thick) and then processed for
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analyzed from at least 5 mice in each experimental group.
Antibodies and confocal imaging
Primary antibodies used were as follows: Mouse-GFAP
(Chemicon), Rab-GFAP (Dacocytomation), Rab-Olig2 (Chemi-
con), Guinea pig-Olig2 (Gift of Dr. Tom Jessell), Rab-PDGFRa
(Cell Signaling), Rab-Pten (Cell Signaling), Rab-GFP (Invitrogen),
Chicken-GFP (Invitrogen), Rab-ki67 (Vector Lab), Rab-ki67
(Abcam), Guinea pig-NG2 (Gift of Dr. Bill Stallcup), Rab-NG2
(Chemicon), Goat-Doublecortin (Santa Cruz), Rab-Sox2 (Chemi-
con), Mouse-NeuN (Chemicon), Rab-Tcf4 (Millipore), Mouse-
Nkx2.2 (DSHB), Rab-Sox10 (Sigma), Mouse-Nestin (Chemicon),
Hoechst 33342 (Invitrogen). Secondary antibodies were purchased
from Invitrogen, conjugated with Alexa 488, 568 or 647. Z series
confocal images were performed using a Zeiss LSM 510 Meta
under 406oil objective with 1 mm incremental steps. Z series was
then stacked together to generate the projected view. All confocal
pictures shown were projected views. These images were imported
and processed in ImageJ and Adobe Photoshop.
Primary tumor preparation and staining
Primary tumor preparation was generated as described in
Methods S1 [17]. The tumor preparation was plated overnight on
poly-lysine coated dishes. For serial transplantation studies cells
were injected into NOD/SCID mice (as described above). For
immunocytochemical staining, 3610
4 cells per well were plated on
8 well culture chamber slides overnight. Cells were then fixed and
stained the next day as described [17].
Gene Expression
End stage mouse tumors were dissected and snap frozen, and
then shipped on dry ice to Bionomics facility in Rutgers University
for expression array analysis. The platform used was AffymetrixH
GeneChipH Mouse Genome 430A 2.0 Array (AffymetrixH, Santa
Clara, CA). The microarray labeling, hybridization and quality
controls were performed by following AffymetrixH protocol. Raw
data was then normalized and summarized by robust multichip
average (RMA) [80]. The dataset for different neural lineages in the
mouse brains was downloaded from NCBI GEO with the access
number GSE9566 [43]. The complete human GBM datasets
were downloaded from TCGA website (cancergenome.nih.gov),
NCBI GEO with the access number GSE4271, Rembrandt website
(https://caintegrator.nci.nih.gov/rembrandt/) and Broad Insti-
tute (http://www.broadinstitute.org/cgi-bin/cancer/publications/
pub_paper.cgi? mode=view&paper_id=162&p=t) [7,10,44,45].
Mouse and human expression comparison
Microarray data from mouse tumors and TCGA tumors were
summarized and normalized separately. The probes were
summarized to gene level by selecting the probe showing the
highest variability measure as inter-quartile range (IQR). A unified
dataset was generated including 9934 genes. To identify the
human to mouse orthologs, we utilized the gene level sequence
based mapping method, which is based on the reciprocal best
match as available from NCBI HomoloGene (build64) [81,82].
The data was centered around zero by performing a z-score
linear transformation of the expression values. Given the highly
homogenous nature of the mouse samples, we used an across genes
standardization, which provided an optimal estimate of the
standard deviation. This transformation, although still affected
by many variables, makes it possible to directly compare the
expression values to the classifier centroids and to run a rank
correlation based clustering analysis. This dataset was then
hierarchically clustered in an unsupervised manner using Pearson
Correlation and average linkage without leaf order optimization,
limited to the ortholog classifier genes (723 out of 840), and
heatmap was generated to allow visual representation of gene
expression and samples segregation as published [83,84]. We used
TMEV version 4.6 (www.tm4.org).
Classification
We applied two approaches to classify the mouse samples, both
of which used the mouse orthologs mapped from the original
human classifier genes [10]. In the first approach we modified the
centroid classifier as published [10]. We re-computed the centroids
using 723, instead of 840, classifier genes. We used the nearest
centroid-based classification algorithm ClaNC [85] to retest the
human validation set and to predict the mouse samples. The mis-
classification rate in the original human validation set was below
10% compared to what was previously published [10]. In the
second approach, we again used the human training set, and then
averaged the expression values of each gene across samples
belonging to the same GBM subtype. We computed the Pearson
correlation coefficients between the given query mouse sample and
each GBM subtype and assigned it to the class with which it
showed the highest correlation coefficient. These results also allow
us to validate the classification results obtained using the modified
ClaNC classifier [10,85]. We performed this analysis for both the
mouse samples and the human validation set (Table S1), and the
error rate was again below 10% in the human set. With both
methods, the classification of all samples matched.
Comparing mouse tumors and the brain lineage datasets
We used expression data from the murine brain transcriptome
database as published [43], which includes Gene sets that are
specifically enriched in the following cell types: astrocytes,
oligodendrocytes, neurons, OPCs, and cultured astroglial cells
(presented in Table S4, S5, S6, S17 and S21, respectively of Cahoy
et al, 2008). Each of these 5 gene sets contains 80 genes that are
enriched greater than 1.5- fold in the respective cell type. The
OPC list represented genes enriched greater than 1.5-fold in
OPCs compared to myelinating Oligodendrocytes. The cultured
astrocytes list includes genes enriched greater than 1.5-fold in
cultured astroglia compared to in vivo astrocytes. 369 of 400 genes
were mapped to the AffymetrixH GeneChipH Mouse Genome
430A 2.0 Array. We normalized and summarized together our
mouse array raw data and the dataset GSE9566 with RMA. We
computed an unsupervised hierarchical clustering of the combined
dataset using the gene list (369) of different neural lineages. All
gene lists of this study are provided in Table S1.
DGE and Ingenuity
To identify the statistically significant differentially expressed
genes between the two mouse models we used the limma package
[86–88] within R/Bioconductor framework [89–93], due to its
high sensitivity and increased control for false positive rate
compared with other variance modeling strategies [94–97]. For
this specific analysis we normalized the mouse samples using
gcRMA due to its optimal combination between precision and
accuracy [98,99]. For the Ingenuity Pathway AnalysisH (www.
ingenuity.com), we used the genes lists from the differential
expression analysis, at False Discovery Rate 0.1 cutoff, to identified
biological function and diseases that were enriched. The
corresponding p value was calculated with Fisher’s exact test
(Ingenuity reference user guide). The network connections were
identified using Ingenuity Pathways Knowledge Base.
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GSEA [100,101] of the murine neural lineage genes [43] in the
integrated mouse and human GBM data set was conducted as
described [10] and implemented in a matlab script [102].
Expression values were replaced by ranks and the reported
Enrichment Score (ES) was computed as sum of the maximum
deviations above and below zero in the random walk. We set the
exponent to the rank as weight to 1/5 according to the number of
gene classes. GSEA was also used to rank order the tumors on the
basis of the DGE lists generated from comparing two mouse
models. The ES from each gene list was z-scored and the
difference was used to rank-order the samples. The single sample
GSEA was conducted using the GSEA implementation on the
Broad Institute (www.broadinstitute.org/gsea/download) with
DGE gene lists.
Survival Analysis
Kaplan-Meier survival analysis and the Mantel-Cox log-rank
test were performed using Prism 4 (Graphpad software).
Supporting Information
Figure S1 Serially transplanted tumors retained capacity to form
GBM.
(DOC)
Figure S2 Immunophenotypes of tumor cells are consistent with
OPC identity.
(DOC)
Figure S3 Most cells infected by PDGF retrovirus express
markers of OPCs by 17 dpi.
(DOC)
Figure S4 Injecting PDGF retrovirus into SVZ infects progen-
itor cells that gave rise to olfactory neurons.
(DOC)
Figure S5 PDGF driven mouse tumors resemble human
Proneural GBM and express signatures of OPCs.
(DOC)
Table S1
(XLS)
Methods S1
(DOC)
Acknowledgments
We thank Jim Goldman for critical reading of the manuscript, Marcela
Assanah and Sanja Ivkovic for helping with retrovirus preparation, and
Nancy Zhou, Orlando Gil and Julia Sisti for support. We thank Frank
Costantini for YFP mice. We also thank Roel Verhaak, Katie Hoadley,
Neil Hayes, Houtan Noushmehr, and Peter Laird for communicating
results.
Author Contributions
Conceived and designed the experiments: LL PC. Performed the
experiments: LL AMS PG CS. Analyzed the data: LL PC. Contributed
reagents/materials/analysis tools: TL SR JNB. Wrote the paper: LL PC.
References
1. Stiles CD, Rowitch DH (2008) Glioma stem cells: a midterm exam. Neuron 58:
832–846.
2. Huse JT, Holland EC (2010) Targeting brain cancer: advances in the
molecular pathology of malignant glioma and medulloblastoma. Nat Rev
Cancer 10: 319–331.
3. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, et al. (2004)
Gene Expression Profiling of Gliomas Strongly Predicts Survival. Cancer
Research 64: 6503–6510.
4. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, et al. (2005) Integrated
Array-Comparative Genomic Hybridization and Expression Array Profiles
Identify Clinically Relevant Molecular Subtypes of Glioblastoma. Cancer
Research 65: 1678–1686.
5. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, et al. (2005) Gene
expression profiling reveals molecularly and clinically distinct subtypes of
glioblastoma multiforme. Proceedings of the National Academy of Sciences of
the United States of America 102: 5814–5819.
6. Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, et al. (2005) Gene
Expression Profiling and Genetic Markers in Glioblastoma Survival. Cancer
Research 65: 4051–4058.
7. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in neurogenesis. Cancer
Cell 9: 157–173.
8. TCGA (2008) Comprehensive genomic characterization defines human
glioblastoma genes and core pathways. Nature 455: 1061–1068.
9. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated
genomic analysis of human glioblastoma multiforme. Science 321: 1807–1812.
10. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated
genomic analysis identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer
Cell 17: 98–110.
11. Uhrbom L, Hesselager G, Nister M, Westermark B (1998) Induction of brain
tumors in mice using a recombinant platelet-derived growth factor B-chain
retrovirus. Cancer Res 58: 5275–5279.
12. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, et al. (2001) PDGF
autocrine stimulation dedifferentiates cultured astrocytes and induces oligo-
dendrogliomas and oligoastrocytomas from neural progenitors and astrocytes
in vivo. Genes Dev 15: 1913–1925.
13. Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T (2002) Astrocyte
inactivation of the pRb pathway predisposes mice to malignant astrocytoma
development that is accelerated by PTEN mutation. Cancer Cell 1: 157–168.
14. Hesselager G, Uhrbom L, Westermark B, Nister M (2003) Comple-
mentary effects of platelet-derived growth factor autocrine stimulation and
p53 or Ink4a-Arf deletion in a mouse glioma model. Cancer Res 63:
4305–4309.
15. Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, et al. (2005) Somatic
induction of Pten loss in a preclinical astrocytoma model reveals major roles in
disease progression and avenues for target discovery and validation. Cancer
Res 65: 5172–5180.
16. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, et al. (2005) Early inactivation
of p53 tumor suppressor gene cooperating with NF1 loss induces malignant
astrocytoma. Cancer Cell 8: 119–130.
17. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, et al. (2006) Glial
progenitors in adult white matter are driven to form malignant gliomas by
platelet-derived growth factor-expressing retroviruses. J Neurosci 26:
6781–6790.
18. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A,
et al. (2006) PDGFR alpha-positive B cells are neural stem cells in the adult
SVZ that form glioma-like growths in response to increased PDGF signaling.
Neuron 51: 187–199.
19. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, et al. (2008) p53 and
Pten control neural and glioma stem/progenitor cell renewal and differenti-
ation. Nature 455: 1129–1133.
20. Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, et al. (2009) Expression of
mutant p53 proteins implicates a lineage relationship between neural stem cells
and malignant astrocytic glioma in a murine model. Cancer Cell 15: 514–526.
21. Lindberg N, Kastemar M, Olofsson T, Smits A, Uhrbom L (2009)
Oligodendrocyte progenitor cells can act as cell of origin for experimental
glioma. Oncogene 28: 2266–2275.
22. Assanah MC, Bruce JN, Suzuki SO, Chen A, Goldman JE, et al. (2009) PDGF
stimulates the massive expansion of glial progenitors in the neonatal forebrain.
Glia 57: 1835–1847.
23. Hede S-M, Hansson I, Afink GB, Eriksson A, Nazarenko I, et al. (2009) GFAP
promoter driven transgenic expression of PDGFB in the mouse brain leads to
glioblastoma in a Trp53 null background. Glia 57: 1143–1153.
24. Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, et al.
(2009) Development of a novel mouse glioma model using lentiviral vectors.
Nat Med 15: 110–116.
25. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, et al. (2009)
Malignant astrocytomas originate from neural stem/progenitor cells in a
somatic tumor suppressor mouse model. Cancer Cell 15: 45–56.
26. Jacques TS, Swales A, Brzozowski MJ, Henriquez NV, Linehan JM, et al.
(2010) Combinations of genetic mutations in the adult neural stem cell
compartment determine brain tumour phenotypes. EMBO J 29: 222–235.
27. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, et al. (2010) Non-Stem
Cell Origin for Oligodendroglioma. Cancer Cell 18: 669–682.
Adult Glial Progenitors Give Rise to Proneural GBM
PLoS ONE | www.plosone.org 13 May 2011 | Volume 6 | Issue 5 | e2004128. Canoll P, Goldman J (2008) The interface between glial progenitors and
gliomas. Acta Neuropathologica 116: 465–477.
29. Dolores Hambardzumyan NMA, Karim Y. Helmy, Oren J. Becher, Eric C.
Holland (2009) Modeling Adult Gliomas Using RCAS/t-va Technology.
Translational Oncology 2: 89–95.
30. Horner PJ, Power AE, Kempermann G, Kuhn HG, Palmer TD, et al. (2000)
Proliferation and Differentiation of Progenitor Cells Throughout the Intact
Adult Rat Spinal Cord. J Neurosci 20: 2218–2228.
31. Gensert JM, Goldman JE (2001) Heterogeneity of cycling glial progenitors in
the adult mammalian cortex and white matter. Journal of Neurobiology 48:
75–86.
32. Zhu X, Bergles DE, Nishiyama A (2008) NG2 cells generate both
oligodendrocytes and gray matter astrocytes. Development 135: 145–157.
33. Roy NS, Wang S, Harrison-Restelli C, Benraiss A, Fraser RAR, et al. (1999)
Identification, Isolation, and Promoter-Defined Separation of Mitotic Oligo-
dendrocyte Progenitor Cells from the Adult Human Subcortical White Matter.
J Neurosci 19: 9986–9995.
34. Dawson MRL, Polito A, Levine JM, Reynolds R (2003) NG2-expressing glial
progenitor cells: an abundant and widespread population of cycling cells in the
adult rat CNS. Molecular and Cellular Neuroscience 24: 476–488.
35. Rhee W, Ray S, Yokoo H, Hoane ME, Lee CC, et al. (2009) Quantitative
analysis of mitotic Olig2 cells in adult human brain and gliomas: Implications
for glioma histogenesis and biology. Glia 57: 510–523.
36. Chong SYC, Chan JR (2010) Tapping into the glial reservoir: cells committed
to remaining uncommitted. The Journal of Cell Biology 188: 305–312.
37. Geha S, Pallud J, Junier M-P, Devaux B, Leonard N, et al. (2010) NG2+/
Olig2+ Cells are the Major Cycle-Related Cell Population of the Adult Human
Normal Brain. Brain Pathology 20: 399–411.
38. Johnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D,
et al. (2010) Cross-species genomics matches driver mutations and cell
compartments to model ependymoma. Nature 466: 632–636.
39. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, et al. (2010)
Subtypes of medulloblastoma have distinct developmental origins. Nature 468:
1095–1099.
40. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, et al.
(2009) Glioblastoma Subclasses Can Be Defined by Activity among Signal
Transduction Pathways and Associated Genomic Alterations. PLoS One 4:
e7752.
41. Canoll PD, Musacchio JM, Hardy R, Reynolds R, Marchionni MA, et al.
(1996) GGF/neuregulin is a neuronal signal that promotes the proliferation and
survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron
17: 229–243.
42. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, et al. (2004) Dose-
dependent effects of platelet-derived growth factor-B on glial tumorigenesis.
Cancer Res 64: 4783–4789.
43. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, et al. (2008) A
transcriptome database for astrocytes, neurons, and oligodendrocytes: a new
resource for understanding brain development and function. J Neurosci 28:
264–278.
44. Sun L, Hui A-M, Su Q, Vortmeyer A, Kotliarov Y, et al. (2006) Neuronal and
glioma-derived stem cell factor induces angiogenesis within the brain. Cancer
Cell 9: 287–300.
45. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007)
Assessing the significance of chromosomal aberrations in cancer: Methodology
and application to glioma. Proceedings of the National Academy of Sciences
104: 20007–20012.
46. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human
p53-regulated genes. Nat Rev Mol Cell Biol 9: 402–412.
47. Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity
of p53. Cell 137: 413–431.
48. Zhu Y, Prives C (2009) p53 and Metabolism: The GAMT Connection.
Molecular Cell 36: 351–352.
49. Kesari S, Stiles CD (2006) The bad seed: PDGF receptors link adult neural
progenitors to glioma stem cells. Neuron 51: 151–153.
50. Pei Y, Wechsler-Reya RJ (2010) A Malignant Oligarchy: Progenitors Govern
the Behavior of Oligodendrogliomas. Cancer Cell 18: 546–547.
51. Gil-Perotin S, Marin-Husstege M, Li J, Soriano-Navarro M, Zindy F, et al.
(2006) Loss of p53 Induces Changes in the Behavior of Subventricular Zone
Cells: Implication for the Genesis of Glial Tumors. J Neurosci 26: 1107–1116.
52. Ligon KL, Huillard E, Mehta S, Kesari S, Liu H, et al. (2007) Olig2-Regulated
Lineage-Restricted Pathway Controls Replication Competence in Neural Stem
Cells and Malignant Glioma. Neuron 53: 503–517.
53. Bohman L-E (2010) Magnetic Resonance Imaging Characteristics of
Glioblastoma Multiforme: Implications for Understanding Glioma Ontogeny.
Neurosurgery 67: 1319–1328.
54. Lim DA, Cha S, Mayo MC, Chen M-H, Keles E, et al. (2007) Relationship of
glioblastoma multiforme to neural stem cell regions predicts invasive and
multifocal tumor phenotype. Neuro-Oncology 9: 424–429.
55. Kappadakunnel M, Eskin A, Dong J, Nelson S, Mischel P, et al. (2010) Stem
cell associated gene expression in glioblastoma multiforme: relationship to
survival and the subventricular zone. Journal of Neuro-Oncology 96: 359–367.
56. Lewis PF, Emerman M (1994) Passage through mitosis is required for
oncoretroviruses but not for the human immunodeficiency virus. J Virol 68:
510–516.
57. Levison SW, Goldman JE (1993) Both oligodendrocytes and astrocytes develop
from progenitors in the subventricular zone of postnatal rat forebrain. Neuron
10: 201–212.
58. Levison SW, Young GM, Goldman JE (1999) Cycling cells in the adult rat
neocortex preferentially generate oligodendroglia. Journal of Neuroscience
Research 57: 435–446.
59. van Praag H, Schinder AF, Christie BR, Toni N, Palmer TD, et al. (2002)
Functional neurogenesis in the adult hippocampus. Nature 415: 1030–1034.
60. Hart IK, Richardson WD, Heldin CH, Westermark B, Raff MC (1989) PDGF
receptors on cells of the oligodendrocyte-type-2 astrocyte (O-2A) cell lineage.
Development 105: 595–603.
61. Pringle NP, Mudhar HS, Collarini EJ, Richardson WD (1992) PDGF receptors
in the rat CNS: during late neurogenesis, PDGF alpha-receptor expression
appears to be restricted to glial cells of the oligodendrocyte lineage.
Development 115: 535–551.
62. Barres BA, Schmid R, Sendnter M, Raff MC (1993) Multiple extracellular
signals are required for long-term oligodendrocyte survival. Development 118:
283–295.
63. Calver AR, Hall AC, Yu WP, Walsh FS, Heath JK, et al. (1998)
Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron
20: 869–882.
64. McKinnon RD, Waldron S, Kiel ME (2005) PDGF {alpha}-Receptor Signal
Strength Controls an RTK Rheostat That Integrates Phosphoinositol 39-
Kinase and Phospholipase C{gamma} Pathways during Oligodendrocyte
Maturation. J Neurosci 25: 3499–3508.
65. Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P (1988) Platelet-
derived growth factor promotes division and motility and inhibits premature
differentiation of the oligodendrocyte/type-2 astrocyte progenitor ceil. Nature
333: 560–562.
66. Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD (1988) Platelet-
derived growth factor from astrocytes drives the clock that times oligodendro-
cyte development in culture. Nature 333: 562–565.
67. Armstrong RC, Harvath L, Dubois-Dalcq ME (1990) Type 1 astrocytes and
oligodendrocyte-type 2 astrocyte glial progenitors migrate toward distinct
molecules. Journal of Neuroscience Research 27: 400–407.
68. Fruttiger M, Karlsson L, Hall AC, Abramsson A, Calver AR, et al. (1999)
Defective oligodendrocyte development and severe hypomyelination in PDGF-
A knockout mice. Development 126: 457–467.
69. Klinghoffer RA, Hamilton TG, Hoch R, Soriano P (2002) An Allelic Series at
the PDGF6R Locus Indicates Unequal Contributions of Distinct Signaling
Pathways During Development. Developmental cell 2: 103–113.
70. Cooper LAD, Gutman DA, Long Q, Johnson BA, Cholleti SR, et al. (2009)
The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and
Predicts Improved Survival among Diffuse Gliomas. PLoS One 5: e12548.
71. Chow Lionel ML, Endersby R, Zhu X, Rankin S, Qu C, et al. (2011)
Cooperativity within and among Pten, p53, and Rb Pathways Induces High-
Grade Astrocytoma in Adult Brain. Cancer cell 19: 305–316.
72. Prives C (1998) Signaling to p53: Breaking the MDM2-p53 Circuit. Cell 95:
5–8.
73. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010)
Identification of a CpG island methylator phenotype that defines a distinct
subgroup of glioma. Cancer Cell 17: 510–522.
74. Wright KD, Gilbertson RJ (2010) To Infinium, and Beyond! Cancer Cell 17:
419–420.
75. Matsuda T, Cepko CL (2007) Controlled expression of transgenes introduced
by in vivo electroporation. Proceedings of the National Academy of Sciences
104: 1027–1032.
76. Tashiro A, Zhao C, Gage FH (2006) Retrovirus-mediated single-cell gene
knockout technique in adult newborn neurons in vivo. Nat Protoc 1:
3049–3055.
77. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, et al. (2001) Cre
reporter strains produced by targeted insertion of EYFP and ECFP into the
ROSA26 locus. BMC Dev Biol 1: 4.
78. Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, et al.
(2001) Negative regulation of neural stem/progenitor cell proliferation by the
Pten tumor suppressor gene in vivo. Science 294: 2186–2189.
79. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, et al. (2005) Crucial role
of p53-dependent cellular senescence in suppression of Pten-deficient
tumorigenesis. Nature 436: 725–730.
80. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003)
Exploration, normalization, and summaries of high density oligonucleotide
array probe level data. Biostatistics 4: 249–264.
81. Jo McEntyre JO (2002) The NCBI Handbook; Jo McEntyre JO, ed.
82. Sayers EW, Barrett T, Benson DA, Bolton E, Bryant SH, et al. (2011) Database
resources of the National Center for Biotechnology Information. Nucleic Acids
Research 39: D38–D51.
83. Katagiri F, Glazebrook J (2001) Pattern Discovery in Expression Profiling Data
John Wiley & Sons, Inc.
84. D’Haeseleer P (2005) How does gene expression clustering work? Nat Biotech
23: 1499–1501.
85. Dabney AR (2006) Classification of microarrays to nearest centroids.
Bioinformatics 21: 4148–4154.
86. Jean(ZHIJIN) Wu RI, James MacDonald, Jeff Gentry gcrma: Background
Adjustment Using Sequence Information. R package version 2.16.0.
Adult Glial Progenitors Give Rise to Proneural GBM
PLoS ONE | www.plosone.org 14 May 2011 | Volume 6 | Issue 5 | e2004187. Smyth G (2004) Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol 3.
88. Smyth GK (2005) Limma: linear models for microarray data. In: R. Gentleman
VC, S. Dudoit, R. Irizarry, W. Huber, eds. Bioinformatics and Computa-
tional Biology Solutions using R and Bioconductor. New York: Springer. pp
397–420.
89. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy analysis of Affymetrix
GeneChip data at the probe level. Bioinformatics 20: 307–315.
90. Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biology 5: R80.
91. Gentleman RCV, Huber W, Irizarry R, Dudoit S, S (2005) Bioinformatics and
Computational Biology Solutions Using R and Bioconductor. 473 p.
92. Wilson CL, Miller CJ (2005) Simpleaffy: a BioConductor package for
Affymetrix Quality Control and data analysis. Bioinformatics 21: 3683–3685.
93. Team R (2009) R Development Core Team R: A language and environment
for statistical computing. R Foundation for Statistical Computing, Vienna,
Austria.
94. Kooperberg C, Aragaki A, Strand AD, Olson JM (2005) Significance testing for
small microarray experiments. Statistics in Medicine 24: 2281–2298.
95. Jeffery I, Higgins D, Culhane A (2006) Comparison and evaluation of methods
for generating differentially expressed gene lists from microarray data. BMC
Bioinformatics 7: 359.
96. Murie C, Woody O, Lee A, Nadon R (2009) Comparison of small n statistical
tests of differential expression applied to microarrays. BMC Bioinformatics 10:
45.
97. Jeanmougin M, de Reynies A, Marisa L, Paccard C, Nuel G, et al. (2010)
Should We Abandon the t-Test in the Analysis of Gene Expression Microarray
Data: A Comparison of Variance Modeling Strategies. PLoS One 5: e12336.
98. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F (2004) A
Model-Based Background Adjustment for Oligonucleotide Expression Arrays.
Journal of the American Statistical Association 99: 909–917.
99. Irizarry RA, Wu Z, Jaffee HA (2006) Comparison of Affymetrix GeneChip
expression measures. Bioinformatics 22: 789–794.
100. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, et al.
(2003) PGC-1[alpha]-responsive genes involved in oxidative phosphorylation
are coordinately downregulated in human diabetes. Nat Genet 34: 267–273.
101. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005)
Gene set enrichment analysis: A knowledge-based approach for interpreting
genome-wide expression profiles. Proceedings of the National Academy of
Sciences of the United States of America 102: 15545–15550.
102. Lim WKLE, Califano A (2009) Master regulators used as breast cancer
metastasis classifier. Pac Symp Biocomput. pp 504–515.
Adult Glial Progenitors Give Rise to Proneural GBM
PLoS ONE | www.plosone.org 15 May 2011 | Volume 6 | Issue 5 | e20041